Results 191 to 200 of about 19,002,199 (367)

A rapid, semiautomated method for apolipoprotein E genotyping. [PDF]

, 1993
Chunxue Guo, Peter Marynen, J.-J. Cassiman   +2 more
openalex   +1 more source

Apolipoprotein E [PDF]

, 2011
openaire   +1 more source

Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics

Proteins: Structure, Function, and Bioinformatics, EarlyView., 2023
Abstract Before the controversial approval of humanized monoclonal antibody lecanemab, which binds to the soluble amyloid‐β protofibrils, all the treatments available earlier, for Alzheimer's disease (AD) were symptomatic. The researchers are still struggling to find a breakthrough in AD therapeutic medicine, which is partially attributable to lack in ...
Sharif Arar, Md Anzarul Haque, Rakez Kayed   +2 more
wiley   +1 more source

Regulation of serum apolipoprotein E metabolism: role of chylomicron metabolism.

, 1982
J G DeLamatre, Brian R. Krause, Paul S. Roheim   +2 more
openalex   +1 more source

Apolipoprotein E to B Ratio: A Marker for Type III Hyperlipoproteinaemia [PDF]

, 1993
Winfried März, Giso Feussner, R. Siekmeier, Bettina Donnerhak, Ludwig Schaaf, Viktor Růžička, Gross Wl   +6 more
openalex   +1 more source

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

CPT: Pharmacometrics &Systems Pharmacology, Volume 11, Issue 12, Page 1578-1591, December 2022., 2022
Abstract Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) and PK/pharmacodynamic (PD) analyses for amyloid plaques, as measured using positron emission tomography (PET), and ...
Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, Ziad Hussein   +8 more
wiley   +1 more source

Lipolysis-induced degradation of apolipoproteins B and E of human very low density lipoproteins.

, 1986
B H Chung, J H Im, Hazel R. Bowdon
openalex   +1 more source

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 62-73, January 2023., 2023
Abstract Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the design of clinical trials in AD.
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino   +15 more
wiley   +1 more source

Studies on stroke-prone spontaneously hypertensive rats(SHRSP) fed a high-fat and high-cholesterol diet. Changes in serum concentrations and distributions of apolipoproteins A-I, A-IV and E.

, 1989
Hiroshi Ogawa, Tomoyo Nishikawa, Shinichi Fukushima, Sukenari Sasagawa   +3 more
openalex   +2 more sources

Temporal Profiling of Male Cortical Astrocyte Transcription Predicts Molecular Shifts From Early Development to Aging

Glia, EarlyView.
Comprehensive analysis of cortical astrocyte gene expression across the lifespan. Profiling dynamic changes of key astrocyte genes reveals functional shifts. Astrocytes contribute to gene‐length‐dependent transcription decline in the aging brain. ABSTRACT Astrocytes are the most abundant glial cell type in the central nervous system (CNS).
Xiaoran Wei, Jiangtao Li, Michelle L. Olsen   +2 more
wiley   +1 more source